Onconova On The Edge After Phase III Rigosertib MDS Failure
Switch To Oral Version But Not For MDS
Onconova’s lead product, rigosertib, has failed in a Phase III study in myelodysplastic syndromes, sending its share price tumbling by 66%.
You may also be interested in...
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to Scrip about what’s coming next from the UK major’s cancer pipeline.
Moderna takes the next step in the in the development of COVID-19 vaccines, with the first approval of the first bivalent vaccine that can produce a broader immune response to new SARS-CoV-2 variants.
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.